Results 81 to 90 of about 5,860 (175)

Outcomes Following Alemtuzumab Induction in Deceased Donor Kidney Transplantation According to Recipient Age Categories: A Single Center Report

Clinical Transplantation, Volume 40, Issue 6, June 2026.
ABSTRACT Introduction The effects of induction therapy with the anti‐CD52 monoclonal antibody alemtuzumab on age‐specific outcomes following kidney transplantation (KT) remain inadequately studied. This study aimed to analyze the comparative safety and efficacy of single‐dose alemtuzumab induction in deceased donor (DD) KT recipients according to ...
Alex Ng, David I. Harriman, Alan C. Farney, Giuseppe Orlando, Colleen Jay, Amber Reeves‐Daniel, Robert J. Stratta   +6 more
wiley   +1 more source

Step-wise evolution of azole resistance through copy number variation followed by KSR1 loss of heterozygosity in Candida albicans.

PLoS Pathogens
Antimicrobial drug resistance poses a global health threat, requiring a deeper understanding of the evolutionary processes that lead to its emergence in pathogens. Complex evolutionary dynamics involve multiple mutations that can result in cooperative or
Pétra Vande Zande, Cécile Gautier, Nora Kawar, Corinne Maufrais, Katura Metzner, Elizabeth Wash, Annette K Beach, Ryan Bracken, Eli Isael Maciel, Nívea Pereira de Sá, Caroline Mota Fernandes, Norma V Solis, Maurizio Del Poeta, Scott G Filler, Judith Berman, Iuliana V Ene, Anna Selmecki   +16 more
doaj   +1 more source

The Effect of Efavirenz and Rufinamide on the Pharmacokinetics and Safety of Quizartinib: Two Phase 1 Studies in Healthy Participants

Clinical and Translational Science, Volume 19, Issue 6, June 2026.
ABSTRACT Quizartinib is an oral, potent, selective FMS‐like tyrosine kinase 3 (FLT3) inhibitor, approved for the treatment of FLT3‐internal tandem duplication (ITD)–positive acute myeloid leukemia (AML) and under investigation in patients with newly diagnosed FLT3‐ITD–negative AML.
YoungJun Yoo, Hamim Zahir, Shinichi Inaba, Kyoin Koo, Tushar Garimella, Malaz Abutarif, Ming Zheng, Emi Kamiyama, Yuan Xu   +8 more
wiley   +1 more source

Utilization of Healthy Volunteers in Oncology Drug Development in Japan: A 10‐Year Analysis of Approved Anticancer Agents (2014–2024)

Clinical and Translational Science, Volume 19, Issue 6, June 2026.
ABSTRACT Anticancer agents with favorable safety profiles, such as immunomodulators and molecular‐targeted agents, are increasingly used in recent cancer therapy, and clinical trials for these agents increasingly incorporate healthy volunteers as well as cancer patients.
Kana Morihisa, Hiroyuki Yoshitsugu, Hirokazu Wakuda, Naoto Uemura   +3 more
wiley   +1 more source

Clearing the FoG: Antifungal tolerance is a subpopulation effect that is distinct from resistance and is associated with persistent candidemia

, 2017
Drug susceptibility, defined by the minimal inhibitory concentration (MIC), often does not predict whether fungal infections will respond to therapy in the clinic.
Alexander Rosenberg, Alon M. Dahan, Iuliana V. Ene, Ella Shtifman Segal, Arnaldo L. Colombo, Maayan Bibi, Naomi Ziv, Judith Berman, Shiri Zakin, Richard J. Bennett   +9 more
core   +1 more source

The Global Antifungal Susceptibility Epidemiology of Trichophyton indotineae Indicating Voriconazole as an Alternative Therapy for Recalcitrant Dermatophytosis

Mycoses, Volume 69, Issue 6, June 2026.
ABSTRACT Background The emergence of Trichophyton indotineae as a multidrug‐resistant dermatophyte has challenged conventional therapeutic approaches for dermatophytosis, leading to a significant therapeutic dilemma. The absence of formal epidemiological cutoff values (ECVs) under the Clinical and Laboratory Standards Institute (CLSI) framework has led
Ge Song, Wenting Xie, Xiaodong She, Weida Liu, Xiaofang Li, Guanzhao Liang   +5 more
wiley   +1 more source

Possible Inhibitory Molecular Mechanism of Farnesol on the Development of Fluconazole Resistance in Candida albicans Biofilm

, 2012
Candida albicans biofilm infections are usually treated with azole antifungals such as fluconazole. However, the development of resistance to this drug in C.
Li-hua Yu, Ming Ma, Xiao-jun Chen, Xin Wei, Shuang-bo Xu   +4 more
core   +1 more source

Fluconazole-induced actin cytoskeleton remodeling requires phosphatidylinositol 3-phosphate 5-kinase in the pathogenic yeast Candida glabrata

, 2018
Known azole antifungal resistance mechanisms include mitochondrial dysfunction and overexpression of the sterol biosynthetic target enzyme and multidrug efflux pumps.
Sapan Borah, Borah, Sapan, Raju Shivarathri, Choudhary, Deepak Kumar, Rupinder Kaur, Shivarathri, Raju, Priyanka Bhakt, Deepak Kumar Choudhary, Bhakt, Priyanka, Kaur, Rupinder   +9 more
core   +1 more source

Loss of Upc2p-Inducible ERG3 Transcription Is Sufficient To Confer Niche-Specific Azole Resistance without Compromising Candida albicans Pathogenicity

mBio, 2018
Inactivation of sterol Δ5,6-desaturase (Erg3p) in the prevalent fungal pathogen Candida albicans is one of several mechanisms that can confer resistance to the azole antifungal drugs.
Arturo Luna-Tapia, Hubertine M. E. Willems, Josie E. Parker, Hélène Tournu, Katherine S. Barker, Andrew T. Nishimoto, P. David Rogers, Steven L. Kelly, Brian M. Peters, Glen E. Palmer   +9 more
doaj   +1 more source

Characteristics of Candida isolates from patients with diabetes mellitus.

, 2006
The present research has investigated the molecular characterization of oral yeasts in healthy individuals from different dental clinical settings in the United Kingdom, and patients from the UK and Italy who were affected by diabetes mellitus (DM) to ...
Manfredi, M.
core